Assessment of the Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Insufficiently Controlled With Basal Insulin +/- Metformin
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01632163|
Recruitment Status : Completed
First Posted : July 2, 2012
Last Update Posted : June 15, 2015
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
- To assess the effects on glycemic control of lixisenatide in comparison to placebo as an add-on treatment to basal insulin with or without metformin in terms of HbA1c reduction over a period of 24 weeks in insufficiently controlled type 2 diabetic patients.
To assess the effects of lixisenatide over 24 weeks on :
- percentage of patients reaching HbA1c<7% or ≤6.5%,
- 2-hour postprandial plasma glucose (PPG) and plasma glucose (PG) excursions during standardized meal challenge test,
- fasting plasma glucose (FPG),
- change in 7-point self-monitored plasma glucose (SMPG) profile),
- body weight,
- change in daily basal insulin dose.
- To assess lixisenatide safety and tolerability.
- To assess anti-lixisenatide antibody development.
|Condition or disease||Intervention/treatment||Phase|
|Type 2 Diabetes Mellitus||Drug: Lixisenatide (AVE0010) Drug: Placebo||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||447 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Investigator, Outcomes Assessor)|
|Official Title:||A Randomized, Double-blind, Placebo-controlled, 2-arm Parallel-group, Multicenter Study With a 24-week Treatment Period Assessing the Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Insufficiently Controlled With Basal Insulin With or Without Metformin|
|Study Start Date :||October 2012|
|Actual Primary Completion Date :||May 2015|
|Actual Study Completion Date :||May 2015|
24-week treatment with lixisenatide once daily on top of basal insulin with or without metformin (at least 1.0g/day)
Drug: Lixisenatide (AVE0010)
Route of administration: subcutaneous injection
Placebo Comparator: Placebo
24-week treatment with placebo once daily on top of basal insulin with or without metformin (at least 1.0g/day)
Route of administration: subcutaneous injection
- Change in HbA1c [ Time Frame: from baseline to week 24 ]
- Percentage of patients with HbA1c <7%, =<6.5% [ Time Frame: at week 24 ]
- Change in 2-hour postprandial plasma glucose and plasma glucose excursion [ Time Frame: from baseline to week 24 ]
- Change in fasting plasma glucose [ Time Frame: from baseline to week 24 ]
- Change in 7-point self monitoring plasma glucose profile (average and each point) [ Time Frame: from baseline to week 24 ]
- Change in body weight [ Time Frame: from baseline to week 24 ]
- Change in daily basal insulin dose [ Time Frame: from baseline to week 24 ]
- Number of patients with adverse events [ Time Frame: 24 weeks ]
- Anti-lixisenatide antibody assessment [ Time Frame: from baseline to week 24 ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
Inclusion criteria :
- Patients with type 2 diabetes mellitus (T2DM) diagnosed for at least 1 year at the time of the screening visit insufficiently controlled with basal insulin± metformin.
- Age < legal age of adulthood.
- HbA1c<7% or >10.5%.
- Basal insulin treatment has not been at a stable regimen for at least 3 months and at a stable dose (± 20%) of at least 15 U/day for at least 2 months prior to screening visit.
- If metformin is given, metformin treatment has not been at a stable dose of at least 1.0 g/day for at least 3 months prior to screening visit.
- History of hypoglycemia unawareness.
- Body Mass Index (BMI) ≤20 kg/m².
- Use of other oral or injectable glucose-lowering agents other than basal insulin or metformin within 3 months prior to the time of screening.
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01632163
|Study Director:||Clinical Sciences & Operations||Sanofi|
|Other Study ID Numbers:||
U1111-1124-1213 ( Other Identifier: UTN )
|First Posted:||July 2, 2012 Key Record Dates|
|Last Update Posted:||June 15, 2015|
|Last Verified:||June 2015|
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Endocrine System Diseases
Physiological Effects of Drugs